U.S. stock night trading volatility: Zynex surged 8.94% in after-hours trading, with active capital inflow attracting market attention

U.S. Stock Night Market Movements Zynex rose 8.94% in the night market, with no significant news recently. Trading is active, and capital flows are evident. Considering the sector and industry trends, the stock shows significant volatility, and specific reasons need further observation. Stocks with High Trading Volume in the Industry Intuitive Surgical fell 0.26% in the night market. Based on recent key news: On December 1, Intuitive Surgical's board chairman Guthart Gary S submitted an application to sell restricted securities, planning to sell 22,806 shares. This insider trading may trigger short-term pressure on the company's stock, leading to price fluctuations. Source: SEC announcement On November 30, Intuitive Surgical is considered a key player in the AI-driven medical market. Despite its high price-to-earnings ratio, its innovative da Vinci surgical system and strong financial health have led to good market performance. Analysts have given positive ratings, and technical indicators show a good outlook. Source: Zhitong Finance On November 29, market competition has intensified. Although Intuitive Surgical has a first-mover advantage and a large installed base, competitive pressure from companies like Medtronic and Johnson & Johnson has increased. The growth of the aging population is expected to maintain its market dominance. Source: Wall Street Insight on the intensifying competition in the medical device industry, with evident capital inflows. TransMedics rose 1.04% in the night market. There is no significant news recently; trading is active, and capital flows are evident. Considering the sector and industry trends, the stock shows significant volatility, and specific reasons need further observation. no_news ResMed fell 0.33% in the night market. Based on recent key news: On December 1, ResMed executive Michael J. Rider plans to sell 50 shares of common stock, valued at $12,208. This transaction is a small-scale sale and is expected to have no significant impact on the company's operations or market position. Source: Company announcement On November 30, MarketBeat pointed out that ResMed was not included among the five stocks recommended by top analysts. Although ResMed currently has a moderate buy rating among analysts, top analysts believe that the other five stocks are more attractive. Source: MarketBeat, with a noticeable decline in market attention towards ResMed and evident capital outflows